NeoGenomics Third Quarter 2026 Earnings Call - NEOGENOMICS INC

Explicit Guidance:

• FY2026 Revenue: Raised to $807–$809 million (midpoint ~$808M), implying ~11% year-over-year growth; previously $802–$806 million.
• FY2026 Adjusted EBITDA: Raised to approximately $60 million (previously $56–$58 million), representing ~40% YoY growth.
• FY2026 Adjusted Gross Margin: Expects >150 basis points of improvement for the full year; Q4 2026 margin anticipated at approximately 48%.
• FY2026 Revenue Mix Assumptions: Clinical revenue growth in the low teens; NGS revenue growth >25% (approaching ~$250M); Non-clinical business expected to decline low double digits.
• 2027 Outlook (Forward-Looking): No formal 2027 guidance provided, but management expects strong momentum and accelerating revenue driven by NGS and MRD, with meaningful revenue contributions from RadarST expected in 2028 and beyond.
• Q4 2026 Volume Growth: Anticipated to be approximately 3% (normalized rate).

Business-Segment Outlook:

• NGS (Next-Generation Sequencing):
  • Growth: Large-panel volume growth >25%; total NGS revenue growth >25% for FY2026.
  • Mix Shift: Large panels vs. targeted panels volume approaching 50-50; mix shift to higher-value large panels expected to drive sustained AUP growth in 2027.
  • Hematology: New therapies driving demand; flagship neoComprehensive Heme panel upgraded (UVA1 detection, variants at <3% allele fraction).
  • Solid Tumor: PanCancer Pro, Tissue, and LBx seeing strong uptake; LBx benefiting from managed care reimbursement tailwinds following MolDX decision.
  • Portfolio Penetration: Therapy selection penetration in community settings estimated at 35–40%, implying substantial room for growth.
  • Halo Effect: Strong integration driving multi-product adoption (e.g., PanCancer Pro → RadarST).
• MRD (Minimal Residual Disease):
  • RadarST: Expected to approach two-thirds of clinical revenue long-term (currently ~33% of clinical revenue).
  • MolDX Reimbursement: One additional indication expected by year-end 2026; second indication expected by mid-2027.
  • Market Opportunity: IO monitoring estimated as a <US$4 billion U.S. market (~400k Stage 4 patients, ~40% on Medicare).
  • Commercial Expansion: A leading regional commercial plan covers RadarST for all MolDX-reimbursed indications effective December 15.
  • Clinical Volumes: Month-over-month improvement post-august MolDX decision; 30% attach rate to other Neogenomics tests.
  • Next-Gen Assay: Whole-gene assay data generation expected next year; potential clinical launch in 2029.
• Non-Clinical:
  • Pharma Services: Exiting low-margin, commoditized legacy contracts; focus shifting to high-value services. Legacy pharma expected to decline low single digits in 2027, while Oncology Data Solutions (ODS) (real-world evidence) shows double-digit growth and is a strategic enabler.
• Oncology Data Solutions (ODS): Growing double-digits; high-margin business leveraging community-based whole-genome data sets.

Market and Competitive Outlook:

• Community Setting: Focus on precision oncology in the community, where ~80% of patients are treated; ~60% of patients currently lack access to comprehensive genomic profiling.
• Payer Dynamics: Continued success with managed care payers (MCOs) and commercial plans; expanding reimbursement for RadarST and PanCancer LBx.
• Competitive Landscape: Differentiation via integrated portfolio (diagnosis to surveillance) and workflow simplification; taking share from large CLIA labs by offering broader test menus and "halo" effects.
• Pricing (AUP): Expecting mid-single-digit AUP growth in a normalized environment; current Q3 growth of 11% was elevated due to exit of a specific high-volume, low-value customer; mix shift to large panels and RCM initiatives will support pricing.
• Market Share: No specific share gain numbers disclosed, but "robust new customer acquisition" and "incremental volumes from existing customers" cited as growth drivers.

Macro / Industry Outlook:

• 2027 Medicare Rates: Preliminary 2027 rates expected to have a "relatively low" impact (low to mid-single digit millions in revenue exposure); confidence remains in AUP growth offsetting any fee cuts; will require operational discipline but not a "big headwind."
• FX/Rates/Regulation: No specific mentions of foreign exchange or broader interest rate impacts. Regulatory focus remains on MolDX coverage and commercial payer negotiations.
• Supply Chain/Infrastructure: Transition to NovaSeq X sequencers for the Heme NGS portfolio expected in H1 2027; full portfolio transition impact on margins anticipated in H2 2027 and early 2028.

Strategic Initiatives:

• Leadership Transition: Warren Stone becomes CEO effective January 4, 2027; Tony Zuck becomes Executive Chair. Strategy remains unchanged; continuity emphasized.
• Sales Force Expansion: Sales resources at 160+ at end of Q3; plan to expand in Q4 2026 and into 2027 in a "disciplined manner."
• Lab of the Future / Digital Transformation:
  • RCM Platform: Transition to Zyfin (Revenue Cycle Management) completed; temporary receivables impact expected to normalize by Q4 2026/early 2027.
  • Sequencers: Capital expenditure of >US$5M in Q3 for Novaseq X transition; upgrades to data servers.
  • AI/Pathology: Expanded partnership with Indica Labs for AI-driven digital pathology to support diagnosis/therapy selection and improve operational efficiency.
  • EMR Integration: Improving connectivity via EPIC Aura and near-future Flatiron integrations; real-time order status tracker launched.
• R&D Investment: Increased 13% YoY in Q3; expected to rise to ~7% of revenue in 2027 (up from 4–5%) to fund indications growth and next-gen products.
• G&A Efficiency: Targeting continued reduction of G&A as a percentage of revenue to offset growth investments.
• Investor Relations: Planned Investor Day scheduled for the first half of 2027.

Risks and Headwinds to Outlook:

• Reimbursement Timing: Dependence on MolDX covering additional indications for RadarST (2 pending); commercial payer negotiations may take time to ramp revenue.
• Operational Transition: Temporary impact on cash flow and receivables from Zyfin RCM platform implementation and Novaseq X migration.
• Payment Settlements: $10 million DOJ settlement payment made in Q3; residual effects on cash flow noted.
• Legacy Business Exit: Continued decline in low-margin legacy pharma contracts.
• Regulatory/Rate Risks: 2027 Medicare fee cuts (low single-digit million exposure) impacting EBITDA flow-through if not offset by AUP growth.
• Implementation Risks: "Lab of the Future" benefits (Novaseq X efficiency) not fully realized until H2 2027; early transition may involve lower-margin MRD volume before reimbursement is secured.

Management Tone on the Future:

• Confidence: High; described business as being in a "position of strength" with "consistent, durable growth."
• Strategy: Clear emphasis on "accelerating execution" of an existing, unchanging strategy focused on "higher value advanced testing modalities" (NGS, MRD, Whole Genome).
• Growth Expectations: Anticipates "durable and accelerating revenue growth" and "discipline margin expansion" as the business shifts from volume-heavy to value-heavy.
• Transition: Expressed strong confidence in Warren Stone's ability to lead; emphasizes continuity of the leadership team and strategy.
• Tone on MRD: Cautiously optimistic; acknowledging a ramp period but emphasizing "strong momentum" expected in 2027.